You’ve never launched here before. We have. Entering a new therapy area means making big calls on incomplete information and living with them for years. Market due diligence replaces the guesswork with a picture of how the Nordic patient pathway actually works. Talk to us about your therapy area Consulting > Nordic Market Insights > Market Due Diligence Market Due Diligence Entering uncharted territory feels like this Not because the team lacks competence. But because the information exists in fragments and nobody has put them together yet. “We think we understand the pathway. We’re not certain.” Where patients actually enter, how long diagnosis takes, and who decides what the real picture is rarely the one in the slide deck. “Everyone has a theory about the barriers.” Medical, market access and commercial each see a different obstacle and without shared evidence, the loudest theory wins. “We’re busy. But are we working on the right things?” Effort goes into activities that feel productive, while the decisions that actually shape the launch wait for someone to make them. “We can’t defend this internally.” Global asks why the Nordics need something different – and assumptions don’t hold up in that conversation. Three steps from fragments to direction Senior consultants who combine analytical depth with practical pharma experience and know the Nordic healthcare systems from the inside. 1. Discover Stakeholder interviews with patients, HCPs and payers, combined with real-world evidence and registry analysis, to map how the pathway works today – not how it’s supposed to. 2. Analyze A fit-gap analysis that turns findings into clear learnings: where the pain points are, what’s missing, and what the future pathway could look like. 3. Prioritize A Strategic Launch Roadmap with clear priorities, coordinated actions, defined ownership and KPIs agreed with your cross-functional team. What changes when you know the landscape The same team. The same market. A very different level of confidence in the decisions you make. Before Fragmented information across functions Barriers debated, not evidenced Effort spread across everything at once Decisions made on assumption Each function working from its own picture After due diligence One shared view of the patient pathway Barriers identified and quantified Effort focused where impact is highest Decisions you can defend internally and up A foundation the whole team builds on post-launch Reduce uncertainty. Strengthen your launch decisions. Let’s talk about the therapy area you’re entering and what you’d need to know to move with confidence. Book a dialogue For more information, please contact Amanda G. Hertz Chief Advisor, Nordic Market Insights agh@signumlifescience.com +45 31 65 49 86
